User: Guest  Login
Document type:
Journal Article; Research Support, Non-U.S. Gov't; Article
Author(s):
Ertmer, A; Huber, V; Gilch, S; Yoshimori, T; Erfle, V; Duyster, J; Elsässer, HP; Schätzl, HM
Title:
The anticancer drug imatinib induces cellular autophagy.
Abstract:
The tyrosine kinase inhibitor imatinib (Gleevec, Novartis Pharmaceuticals Corporation; Basel, Switzerland) is a powerful drug for treatment of chronic myelogenous leukemia (CML) and other malignancies. It selectively targets various tyrosine kinases, thereby leading to growth arrest of respective cancer cells. Given its wide application, it is of high importance to know all related underlying molecular mechanisms. We had previously found that imatinib increases the cellular clearance of intrace...     »
Journal title abbreviation:
Leukemia
Year:
2007
Journal volume:
21
Journal issue:
5
Pages contribution:
936-42
Language:
eng
Fulltext / DOI:
doi:10.1038/sj.leu.2404606
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/17330103
Print-ISSN:
0887-6924
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Virologie
 BibTeX